| Does abciximab promote coronary artery remodeling in patients with Kawasaki disease? | |
MedLine Citation:
|
PMID: 20494673 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Standard therapy, consisting of intravenous immunoglobulin and aspirin, reduces, but does not eliminate, coronary artery aneurysms (CAAs) in patients with Kawasaki disease. Large CAAs can persist or undergo varying degrees of regression. The treatment of large CAAs using abciximab has been associated with short-term regression; however, longer term data are unavailable. We sought to obtain longer term follow-up data regarding the changes in the diameters of large CAAs in patients receiving both abciximab and standard therapy and to compare these changes to those of a similar group receiving standard therapy alone. All patients with Kawasaki disease and large CAAs (diameter >5 mm or Z score >10) treated from 1986 to 2007 were identified and divided into 2 groups. The abciximab group received abciximab plus standard therapy and the no-abciximab group received standard therapy alone. The maximum diameters of the proximal right and left anterior descending CAAs were obtained from echocardiograms. The Z scores were calculated for 3 points: the acute/subacute phase (<8 weeks) and at 1 and 3 to 5 years of follow-up. The patients in the abciximab (n = 11) and no-abciximab (n = 7) groups were similar in age, interval to treatment, gender, and largest CAA Z score at diagnosis (19.6 +/- 6.2 vs 25.8 +/- 9.5, p = 0.11). The change in CAA Z score was similar between the 2 groups at 1 year (p = 0.99). At 3 to 5 years of follow-up, compared to baseline, the abciximab group had a greater decrease in the CAA Z score than did the no-abciximab group (-14.0 +/- 4.0 vs -8.2 +/- 5.9, p = 0.04). In conclusion, abciximab treatment might be associated with vascular remodeling in patients with large CAAs. |
Authors:
|
Rachel T McCandless; L Luann Minich; Lloyd Y Tani; Richard V Williams |
Related Documents
:
|
9740343 - Intravascular ultrasound-guided optimized stent deployment. immediate and 6 months clin... 15346093 - The effect of long-term clopidogrel use on neointimal formation after percutaneous coro... 14694953 - Surgery for mitral valvar disease in childhood: should we choose reconstruction or repair? |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2010-04-21 |
Journal Detail:
|
Title: The American journal of cardiology Volume: 105 ISSN: 1879-1913 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-24 Completed Date: 2010-07-08 Revised Date: 2013-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1625-8 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Division of Cardiology, Department of Pediatrics, Primary Children's Medical Center and the University of Utah, Salt Lake City, Utah, USA. rachel.mccandless@hsc.utah.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use* Aspirin / therapeutic use Child Child, Preschool Coronary Vessels / pathology*, ultrasonography Drug Therapy, Combination Female Follow-Up Studies Humans Immunoglobulin Fab Fragments / therapeutic use* Immunoglobulins / therapeutic use Infant Male Medical Records Mucocutaneous Lymph Node Syndrome / drug therapy*, pathology*, ultrasonography Platelet Aggregation Inhibitors / therapeutic use* Retrospective Studies Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Immunoglobulins; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; X85G7936GV/abciximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiovascular anomalies associated with chromosome 22q11.2 deletion syndrome.
Next Document: Aortic root dimensions in elite athletes.